What Happened?
Baltimore, MD-based Delfi-Diagnostics Appointed Doug Schenkel as Chief Financial Officer
About the Company
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
About the Person
Doug Schenkel is Chief Financial Officer at Delfi Diagnostics. Previously, Doug held various senior HR leadership roles in the industry.
Info Source
News
Short Profile